+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Genmab AS - logo

Genmab is a leading biotechnology company that focuses on developing innovative antibody products. Arzerra is the company’s first marketed antibody and is approved to treat chronic lymphocytic leukemia (CLL) patients in all major markets. Another product, Darzalex, has been approved in the United States for the treatment of patients with multiple myeloma. Genmab was founded in Copenhagen, Denmark in 1999 and employs around 200 people.

TRAIL Receptor 2 Agonists - Pipeline Insight, 2025 - Product Thumbnail Image

TRAIL Receptor 2 Agonists - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
From
From
T Cell Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

T Cell Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
TRAIL Receptor 1 & Receptor 2 Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

TRAIL Receptor 1 & Receptor 2 Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
HPV Associated Disorders Market Report 2025 - Product Thumbnail Image

HPV Associated Disorders Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
Advanced Cervical Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Cervical Cancer - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 160 Pages
  • Global
From
Licensing Deals in Pharmaceuticals 2020-2025 - Product Thumbnail Image

Licensing Deals in Pharmaceuticals 2020-2025

  • Report
  • September 2025
  • 1000 Pages
  • Global
From
Bispecific antibody - Competitive landscape, 2023 - Product Thumbnail Image

Bispecific antibody - Competitive landscape, 2023

  • Report
  • May 2023
  • 450 Pages
  • Global
From
From
From
Fallopian Tube Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Fallopian Tube Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Ovarian Cancer- Pipeline Insight, 2025 - Product Thumbnail Image

Ovarian Cancer- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 450 Pages
  • Global
From
Loading Indicator